Cancer Risk with Janus Kinase Inhibitors: Drug-Specific Risks or a Class Effect? A systematic literature review and network meta-analysis across Immune Mediated Inflammatory Diseases (ACR Convergence 2026) - Sep 8, 2026 - Abstract #1889; Pres time: Nov 9, 2026; 01:45 PM - 02:00 PM; Location: W311A-D; In Person; "Eligible comparators were placebo (PBO) and/or methotrexate monotherapy (MTX) or another active comparator. Models allowing treatment-specific JAKi effects provided a better fit than a common class-effect model. While tofacitinib was associated with increased cancer risk relative to TNFi, similar associations were not observed for baricitinib, upadacitinib, or filgotinib. These findings suggest that malignancy risk may vary between JAKi and should not necessarily be assumed to represent a uniform class effect."
Retrospective data • Review • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammatory Arthritis • Inflammatory Bowel Disease • Oncology • Psoriasis • Psoriatic Arthritis • Rheumatoid Arthritis • Seronegative Spondyloarthropathies • Skin Cancer • Solid Tumor
|
|
Mark Gibson; mark russell; Katie Bechman; Victoria Allen; Maryam Adas; Jeremy Brown; Sam Norton; James Galloway
|